Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO <i>resect</i> group

The novel RANO risk model serves as an easy-to-use, yet highly prognostic tool for postoperative patient stratification prior to further therapy. The model may serve to guide patient management and reduce imbalances between study arms in prospective trials.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2024-11-04
DOI
https://doi.org/10.1093/neuonc/noae231
Citations
12
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
5.26

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO resect group

J. C. Tonn, Jacob S. Young, Mitchel Stuart Berger, Levin Häni et al.
12 citations
Neuro-Oncology
Glioma Diagnosis and Treatment
5.26
article

Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO resect group

J. C. Tonn, Jacob S. Young, Mitchel Stuart Berger, Levin Häni, Martin J. van den Bent, Stefan Josef Grau, Daniel P. Cahill, Michael Weller, Jasper K W Gerritsen, Gilbert Youssef, Annette M. Molinaro, Philipp Karschnia, Shawn L. Hervey‐Jumper, Oliver Schnell, Francesco Bruno, Jörg Dietrich, Nico Teske, Patrick Y Wen, Raymond Y. Huang, Niklas Thon, Antonio Dono, Jürgen Beck, Maximilian I. Ruge, Tommaso Sciortino, Lorenzo Bello, Yoshua Esquenazi, Roberta Rudà, Stephanie T Juenger, Michael A. Vogelbaum, Susan M. Chang
article en
12 citations

Abstract

The novel RANO risk model serves as an easy-to-use, yet highly prognostic tool for postoperative patient stratification prior to further therapy. The model may serve to guide patient management and reduce imbalances between study arms in prospective trials.

Neuro-OncologyVol. 27(4)
University of Bern (CH), Brigham and Women's Hospital (US), Harvard University (US), University of Freiburg (DE), University of California, San Francisco (US), University of Cologne (DE), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), University of Milan (IT), University of Zurich (CH), University Hospital of Bern (CH), University Medical Center Freiburg (DE), Moffitt Cancer Center (US), Massachusetts General Hospital (US), University Hospital of Zurich (CH), Center for Neuro-Oncology (US), Neuroscience Institute (IT), Dana-Farber Cancer Institute (US), Center for Cancer Research (US), Erasmus MC Cancer Institute (NL), Klinikum Fulda (DE), The University of Texas Health Science Center (US), Deutsches Konsortium für Translationale Krebsforschung (DE), University of Turin (IT), University of San Francisco (US), Ludwig-Maximilians-Universität München (DE), The University of Texas Health Science Center at Houston (US)
U.S. Department of Defense, Conquer Cancer Foundation, Amgen, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Brigham and Women's Hospital, Massachusetts General Hospital, American Society of Clinical Oncology, Celgene, Boston Scientific Corporation, University of Bern, Moffitt Cancer Center, Università degli Studi di Milano, Novocure, McGovern Medical School, Boston Pharmaceuticals, Incyte, Inselspital, Universitätsspital Bern, Albert-Ludwigs-Universität Freiburg, Universität Zürich, Università degli Studi di Torino, Universität zu Köln, Servier, Deutschen Konsortium für Translationale Krebsforschung, Medac, National Institutes of Health
Openalex Percentile: Top 4%
Glioma Diagnosis and Treatment
5.26
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.